District of Columbia med spa & injectable regulations
What’s changing for med spas and injectors in District of Columbia — GLP-1 compounding, scope-of-practice, and enforcement — plus the federal FDA and Federal Register actions that apply in District of Columbia. Med Spa Radar monitors it all and tells you, in plain language, what changed and what to do.
Opening a med spa? We have not verified District of Columbia’s rules against the statute yet, so start with what opening a med spa requires →
Latest District of Columbia changes
No District of Columbia-specific changes have crossed our radar yet — we’re actively monitoring the District of Columbia legislature and licensing boards. The federal changes below apply to every District of Columbia practice today.
Federal changes that apply in District of Columbia
FDA and Federal Register actions are nationwide — they govern District of Columbia practices too.
- CAUTIONFEDERALFederal RegisterJul 30, 2026
FDA / Federal Register Notice: Outsourcing Facility Fee Rates for Fiscal Year 2027
New FDA fees for outsourcing facilities will impact med spas using compounds.
- CRITICALFEDERALFDA Warning LetterJul 8, 2026
FDA Warning Letter: Spa De Soleil, Inc. (Drugs)
FDA warns Spa De Soleil over drug compounding practices.
- MONITORFEDERALFederal RegisterJun 26, 2026
FDA / Federal Register Notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
FDA extends comment period on GLP-1 compounding decisions.
- CRITICALFEDERALFDA Warning LetterJun 23, 2026
FDA Warning Letter: ketaminelab.org (Drugs)
FDA Warning Letter issued to ketaminelab.org for drugs.
- CRITICALFEDERALFTC EnforcementJun 12, 2026
FTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims
FTC targets deceptive health claims affecting aesthetic practices.
- CAUTIONFEDERALFDA Drug ShortagesJun 11, 2026
FDA shortage: Liraglutide Injection (Injection) — Currently in Shortage
Liraglutide is still on the FDA shortage list for compounding.
What we monitor in District of Columbia
- District of Columbia legislature — bills on injectables, GLP-1s & scope of practice
- District of Columbia Board of Nursing — injector scope & delegation
- District of Columbia Medical Board — physician supervision & ownership rules
- District of Columbia Board of Pharmacy — compounding & 503A/503B
- U.S. FDA — enforcement, warning letters, recalls, shortages
- Federal Register — new rules on compounding & aesthetics
District of Columbia med spa compliance — FAQ
- Where do District of Columbia med spa and injectable regulations come from?
- District of Columbia med spas and injectors are governed by a mix of state and federal authorities — the District of Columbia legislature, and the state's boards of nursing, medicine, and pharmacy, alongside federal bodies like the FDA and the Federal Register. Med Spa Radar monitors all of them for District of Columbia and flags what changed in plain language.
- Does the FDA's GLP-1 compounding guidance apply in District of Columbia?
- Yes — federal FDA actions on GLP-1 compounding (semaglutide, tirzepatide) apply nationwide, including in District of Columbia. We track those federal changes alongside any District of Columbia-specific rules so you see the full picture for your practice.
- How do I keep up with District of Columbia regulatory changes?
- Med Spa Radar sends a free weekly Brief on what changed across District of Columbia, the FDA, and the Federal Register. Members get the exact "what to do" for their states in real time. It's regulatory monitoring, not legal advice.
Get District of Columbia changes as they publish
We scan the District of Columbia legislature and licensing boards daily, plus the FDA and the Federal Register. Free weekly Brief — what changed, in plain language, with the source.
Free · unsubscribe in one click · we never sell your address
← All states · Regulatory monitoring, not legal advice.